CMRX - Chimerix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.05
-0.10 (-2.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.15
Open4.15
Bid3.50 x 900
Ask5.12 x 800
Day's Range3.98 - 4.17
52 Week Range3.96 - 5.94
Volume92,764
Avg. Volume173,828
Market Cap194.507M
Beta1.94
PE Ratio (TTM)N/A
EPS (TTM)-1.55
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.40
Trade prices are not sourced from all markets
  • Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks10 days ago

    Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates

    Chimerix (CMRX) delivered earnings and revenue surprises of 11.36% and 27.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press10 days ago

    Chimerix: 2Q Earnings Snapshot

    On a per-share basis, the Durham, North Carolina-based company said it had a loss of 39 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • GlobeNewswire10 days ago

    Chimerix Announces Second Quarter 2018 Financial Results

    DURHAM, N.C., Aug. 08, 2018-- Chimerix, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported financial results and provided a corporate update for the ...

  • ACCESSWIRE10 days ago

    Chimerix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30 AM Eastern Time. To ...

  • GlobeNewswire17 days ago

    Chimerix to Announce Second Quarter 2018 Financial Results on August 8, 2018

    DURHAM, N.C., Aug. 01, 2018-- Chimerix, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast ...

  • ContraVir Stock Rose on Clinical Trial Progress Report
    Market Realist25 days ago

    ContraVir Stock Rose on Clinical Trial Progress Report

    On July 23, ContraVir Pharmaceuticals stock closed at $0.95, which represents ~12% growth from its 52-week low of $0.85 on July 20 and 4.7% growth from its close of $0.91 on July 20. ContraVir Pharmaceuticals hit its 52-week high of $6.60 on October 17, 2017. On July 23, ContraVir Pharmaceuticals stock started rising after the company gave an update on its phase 1/2A trial of CRV431.

  • GlobeNewswire2 months ago

    New Research: Key Drivers of Growth for Webster Financial, Chimerix, Commerce Bancshares, Teligent, Pinnacle Financial Partners, and Empire State Realty Trust — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Webster ...

  • GlobeNewswire2 months ago

    Chimerix Announces Discovery and Demonstrated Preclinical Activity Supporting Ongoing Phase 1 Study of New Antiviral for Treatment and Prevention of Norovirus

    Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced results from preclinical studies supporting further evaluation of CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. CMX521 showed activity in vitro against all strains of norovirus tested, suggesting broad efficacy against human noroviruses and supporting the ongoing Phase 1 study. The data will be presented in an oral and poster presentation at the 31st International Conference on Antiviral Research (ICAR) hosted by the International Society for Antiviral Research (ISAR) in Porto, Portugal.

  • Benzinga2 months ago

    The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

    The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves . Nektar Therapeutics (NASDAQ: NKTR ) slumped about 42 percent, while Deciphera Pharmaceuticals ...

  • What new FDA designation means for Durham's Chimerix
    American City Business Journals2 months ago

    What new FDA designation means for Durham's Chimerix

    Durham-based biopharma Chimerix has banked a new designation from the U.S. Food and Drug Administration.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Five Below Inc (NASDAQ: FIVE ) stock was trading higher ...

  • GlobeNewswire2 months ago

    Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox

    Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for brincidofovir for the treatment of smallpox. Chimerix has been working with the Biomedical Advanced Research and Development Authority (BARDA) since 2011 to develop brincidofovir as a medical countermeasure for smallpox, demonstrating improved survival rates following confirmed orthopoxvirus infections in multiple animal models.

  • GlobeNewswire2 months ago

    Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)

    Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, announced that President and Chief Executive Officer M. Michelle Berrey, MD, MPH will deliver remarks before the House Committee on Energy and Commerce Subcommittee on Health at the hearing titled “Examining the Reauthorization of the Pandemic and All-Hazards Preparedness Act” at 10 a.m. ET on Wednesday, June 6 in Washington, D.C. The purpose of the hearing is to reauthorize certain programs under the Pandemic and All-Hazards Preparedness Act (PAHPA), which originally passed in 2006 and seeks to improve the United States’ public health and medical preparedness and response capabilities for emergencies, whether deliberate, accidental or natural.  The draft reauthorization legislation would increase funding for the Biomedical Advanced Research and Development Authority (BARDA) and the Project BioShield Special Reserve Fund, a secure funding source for the purchase and stockpile of critical medical countermeasures such as vaccines, therapeutics and diagnostics.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CMRX earnings conference call or presentation 7-May-18 12:30pm GMT

    Q1 2018 Chimerix Inc Earnings Call

  • Want To Invest In Chimerix Inc (NASDAQ:CMRX)? Here’s How It Performed Lately
    Simply Wall St.3 months ago

    Want To Invest In Chimerix Inc (NASDAQ:CMRX)? Here’s How It Performed Lately

    Examining how Chimerix Inc (NASDAQ:CMRX) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense check toRead More...

  • Associated Press3 months ago

    Chimerix: 1Q Earnings Snapshot

    The Durham, North Carolina-based company said it had a loss of 42 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...

  • ACCESSWIRE3 months ago

    Chimerix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 7, 2018 at 8:30 AM Eastern Time. To listen ...

  • Look what Triangle woman just became chairwoman of a $250M company
    American City Business Journals5 months ago

    Look what Triangle woman just became chairwoman of a $250M company

    Amid pushing its antiviral drug forward, Durham-based Chimerix (Nasdaq:CMRX) has made a number of new additions to its board of directors and named a female board chair.

  • Durham pharma pushing to fight a common cold virus that's deadly to some patients
    American City Business Journals5 months ago

    Durham pharma pushing to fight a common cold virus that's deadly to some patients

    For Durham-based Chimerix, fighting a virus known to cause the common cold is not a task it takes lightly.